本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SAN FRANCISCO and SUZHOU, China, Dec. 5, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC). Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, "IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent's deep understanding of these assets, combined with Takeda's extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward." Under the agreement: Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S. Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China. Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China. Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda). Detailed information about the collaboration can be found at the official website of Innovent Biologics. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR-001 and SKB105 on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026 with combination studies to follow CHENGDU, China and WALTHAM, Mass., Dec. 4, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs, and Crescent Biopharma, Inc. ("Crescent") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the companies have entered into a strategic partnership to develop and commercialize oncology therapeutics, including novel combinations. The partnership involves Crescent's CR-001, a PD-1 x VEGF bispecific antibody, and Kelun-Biotech's SKB105, an integrin beta-6 (ITGB6)-directed antibody-drug conjugate (ADC) with a topoisomerase payload. Both candidates are being developed for the treatment of solid tumors and are expected to enter Phase 1/2 monotherapy clinical trials in the first quarter of 2026. Under the terms of the collaboration, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize CR-001 in Greater China (including mainland China, Hong Kong, Macau and Taiwan). In addition, Kelun-Biotech has granted Crescent exclusive rights to research, develop, manufacture and commercialize SKB105 in the United States, Europe and all other markets outside of Greater China. The partnership includes the development of these candidates as monotherapies, and also the evaluation of CR-001 in combination with SKB105.Both Crescent and Kelun-Biotech have the right to independently develop CR-001 in additional combinations, including combinations of CR-001 with proprietary ADC pipeline assets. Dr. Michael Ge, chief executive officer of Kelun-Biotech, said, "We are pleased to have entered into a partnership with Crescent for two innovative assets, CR-001 and SKB105. This collaboration complements and strengthens our differentiated oncology pipeline by the addition of CR-001 and also enables us to advance the development of SKB105 in the global market, bolstering its potential commercial value and our global collaboration network. Our creative global partnership combines the capabilities of both companies to explore novel monotherapies and combination strategies for tumor treatments with SKB105 and CR-001. By leveraging China's abundant clinical resources and execution efficiency, we aim to expedite clinical development while rigorously maintaining the highest global standards. We believe this partnership creates a powerful synergy to maximize the potential of these two drug candidates for the treatment of patients in both China and the rest of the world." "We are thrilled to be partnering with Kelun-Biotech, an established leader in the development and commercialization of ADCs who shares our commitment to bringing next generation therapeutics that can improve outcomes for people living with cancer," said Joshua Brumm, chief executive officer of Crescent. "This collaboration expands our pipeline with the addition of SKB105, furthers our strategy of advancing multiple modalities across our portfolio, and accelerates our efforts to deliver synergistic combinations with CR-001, which has the potential to be a foundational backbone therapy. We look forward to working with Kelun-Biotech to drive innovative therapeutics with the potential to address multiple tumor types and transform cancer care." Under the collaboration, Kelun-Biotech will receive an upfront payment of US$80 million from Crescent and is also eligible to receive additional milestones of up to US$1.25 billion, plus tiered middle single-digit to low double-digit royalties on net sales of SKB105. Kelun-Biotech is also eligible to receive additional payment from Crescent if Crescent undergoes a near-term change of control or enters into a sublicense agreement with a third party. Crescent will receive an upfront payment of US$20 million from Kelun-Biotech and is also eligible to receive additional milestones of up to US$30 million, plus tiered low to middle single digit royalties on net sales of CR-001. About CR-001 (also known as SKB118) CR-001 is a tetravalent bispecific antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. PD-1 checkpoint inhibition is aimed at restoring T cells' ability to recognize and destroy tumor cells, and blocking VEGF is intended for reducing blood supply to tumor cells and inhibiting tumor growth. In preclinical studies, CR-001 demonstrated cooperative pharmacology with increased binding to PD-1 and signal blockade in the presence of VEGF as well as robust anti-tumor activity. CR-001's anti-VEGF activity may also normalize the vasculature at the tumor site, which has the potential to improve the localization and effectiveness of combination therapies, such as the administration of CR-001 with antibody-drug conjugates (ADCs). A global Phase 1/2 trial of CR-001 in patients with solid tumors is anticipated to commence in the first quarter of 2026. About SKB105 (also known as CR-003) SKB105 is a differentiated ADC targeting integrin beta-6 (ITGB6) with a topoisomerase 1 inhibitor payload. ITGB6 is overexpressed in many solid tumors, but shows minimal to no expression in most normal tissues, thereby potentially reducing the risk of systemic toxicity and off-target effects. SKB105 consists of an anti-ITGB6 fully human IgG1 monoclonal antibody conjugated via a stable, clinically validated cleavable linker. The molecule incorporates proprietary Kthiol® irreversible conjugation technology, designed to enhance stability and tumor-specific payload delivery while reducing adverse effects. SKB105 demonstrated a favorable efficacy, safety, and pharmacokinetic (PK) profile in preclinical models. A Phase 1/2 clinical trial of SKB105 in patients with solid tumors is anticipated to commence in the first quarter of 2026. About Kelun-Biotech Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. About Crescent Biopharma Crescent Biopharma's vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. Crescent 's pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow Crescent on LinkedIn and X. Forward-Looking Statements of Crescent Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the expected benefits or opportunities with respect to the strategic partnership between Crescent and Kelun-Biotech, the ability for each of CR-001 and SKB105 (CR-003) to perform as monotherapies and in combination, the potential for CR-001 to be developed in additional combinations, including with proprietary ADC pipeline assets, the initiation, timing, progress, and results of clinical trials for CR-001 and SKB105 (CR-003), including the initiation of Phase 1/2 monotherapy clinical trials in the first quarter of 2026, Crescent's expectations regarding the potential benefits of the strategic partnership with Kelun-Biotech, the potential benefits of treatment with and the market for CR-001, and our expectations regarding milestone, royalty, or other payments that could be due under the license agreements. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Crescent will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Crescent's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the expected benefits of, and opportunities related to, the strategic partnership between Crescent and Kelun-Biotech may not be realized by either party or may take longer to realize than anticipated, that the potential of CR-001 and/or SKB105 (CR-003), each as monotherapy and in combination, may change, that CR-001 may not be developed in additional combinations, including with proprietary ADC pipeline assets, that either party may fail to discover and develop any commercially successful product candidates through the strategic partnership, that such product candidates may not receive regulatory approval and, if approved, such product candidates may not be commercially successful, Crescent's limited operating history, including with respect to clinical trials, Crescent's historical losses and any future ability to generate revenue, Crescent's ability to raise capital to support its business plans, risks associated with clinical development and regulatory approval, risks related to Crescent's intellectual property, Crescent's reliance on third parties, including to help develop its product candidates and run its clinical trials, as well as to manufacture its product candidates, Crescent's dependence on key personnel, Crescent's estimates of market opportunity may prove to be inaccurate, significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks, as well as those factors more fully described in Crescent's most recent filings with the Securities and Exchange Commission (including its most recent Quarterly Report on Form 10-Q), and Crescent's other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Crescent.
The strategic alliance aims to elevate S.Pellegrino's premium lifestyle positioning, expand engagement with younger audiences and enhance its global brand offering. MILAN, Dec. 4, 2025 /PRNewswire/ -- S.Pellegrino, the iconic sparkling mineral water brand, today announces a long-term global partnership with Ferrari, underscoring a joint interest in promoting their common values: Italian heritage and culture, craft, and the drive to excellence. Under the agreement, S.Pellegrino will collaborate with Scuderia Ferrari HP, the Formula 1 racing team, and Ferrari Challenge Trofeo Pirelli, the single-makes motorsport championship created in 1993. To view the Multimedia News Release, please click:https://www.multivu.com/s_pellegrino/9370451-en-announces-long-term-partnership-with-ferrari This partnership brings together two Italian brands, uniting their rich heritage, craftsmanship, and commitment to performance. Rooted in S.Pellegrino's purpose — to nurture the art of tasteful living — the collaboration aims to inspire consumers to "Bring their Best". Nestlé Waters & Premium Beverages CEO, Muriel Lienau, explains her vision behind this partnership: "S.Pellegrino and Ferrari are deeply rooted in a rich Italian tradition. This alliance leverages their iconic status and cultural relevance to drive global growth, strengthen S.Pellegrino's position as a premium lifestyle brand, and increase engagement with younger audiences through authentic and innovative brand experiences ." S.Pellegrino shares more than a country of origin with Ferrari — they share a tradition.For over 125 years, S.Pellegrino has celebrated the art of tasteful living, shaping authentic Italian values into experiences admired around the world. This partnership builds on that common heritage. The partnership will deliver unique, co-branded consumer-facing activations that celebrate and blend Italian heritage with modern, premium lifestyle experiences, from exclusive product collaborations with Ferrari's world-renowned design center to immersive and digital-first experiences. With these exclusive activations, S.Pellegrino demonstrates its belief that taste and creativity have the power to transform lives, offering consumers moments that connect, inspire, and elevate everyday experiences. S.Pellegrino will also host a series of global events over the next years, bringing together culinary pioneers, visionary designers, cultural tastemakers and Formula 1 personalities. These in-person gatherings will embody S.Pellegrino's ambition to inspire an appetite for life in younger consumers by encouraging shared connections, creativity and nourishing experiences. "This partnership is a natural evolution of our ongoing ambition to elevate the consumer experience, rooted in our common belief that life is richer when lived with depth and meaning. Both brands share a passion for creating moments that matter – moments defined by quality, beauty, and connection – and this partnership invites consumers to embrace the best of what life has to offer. We have united the best of Italy so that you can bring yours!" says Elisa Gregori, Global CMO for Nestlé Waters & Premium Beverages "Ferrari has always drawn strength from the Italian spirit, founded on craftsmanship, beauty, and the constant pursuit of improvement. In S.Pellegrino we find more than a partner: we see an expression of the same values that guide us: passion, attention to detail, and the desire to elevate every experience. Just as S.Pellegrino refine the everyday into something special, we strive to push performance further, race after race. United by heritage and vision, we aim to bring fans and consumers experiences that feel unmistakably Italian and boldly future-driven, building a connection with the next generation rooted in what we proudly share." Says Lorenzo Giorgetti, Chief Racing Revenues Officer for Ferrari S.p.A. This partnership marks a new chapter in S.Pellegrino's 125-year journey, started in Italy on the Italian Alps surrounding Bergamo and still true to our unique origin and production site, a mark of quality and excellence. We believe in the power of nurturing the art of tasteful living and celebrate the Italian spirit that continues to drive both brands forward: a spirit defined by creativity, taste, and the relentless pursuit of excellence. The partnership will be announced and magnified by communication assets touching digital, print, outdoor and PR in all key cities around the world. Stay tuned. S.PELLEGRINO BOILERPLATE S.Pellegrino is an international brand of Sanpellegrino S.p.A., based in Milan, Italy. Distributed in over 150 countries through subsidiaries and partners across five continents, this mineral water has embodied outstanding quality for more than 125 years thanks to its unique origins, and it perfectly represents Italian style around the world as a blend of pleasure, wellness and balance. With its fine and persistent perlage enhancing freshness and mineral harmony, S.Pellegrino offers a high-level gastronomic experience. Sanpellegrino S.p.A. is a leading company in the Italian beverage sector, with a portfolio that includes mineral waters, non-alcoholic aperitifs and soft drinks. As a producer of mineral water, the company has always been committed to protecting and promoting water as a vital resource for the planet, working responsibly and with dedication to ensure its long-term quality. S.Pellegrino Announces Long-term Partnership with Ferrari to Inspire Consumers to Bring Their Best
Hyundai Motor Group and Air Liquide reaffirm leadership in the hydrogen sector as co-chairs of the Hydrogen Council, driving global hydrogen ecosystem expansion Partnership focuses on building a sustainable energy ecosystem across Europe, U.S. and Korea, encompassing production, storage, transportation and utilization Collaboration expands beyond mobility to include infrastructure, logistics, and clean energy solutions, supporting the global energy transition Major milestones in Korea demonstrate the partnership's progress in FCEV commercialization, refueling infrastructure, and hydrogen supply chain innovation SEOUL, South Korea, Dec. 4, 2025 /PRNewswire/ -- Hyundai Motor Group (the Group) and Air Liquide today announced the expansion of their strategic partnership to accelerate the growth of the global hydrogen ecosystem. (from left to right) François Jackow, Group CEO, Air Liquide; Erwin Penfornis, Group Vice President, Air Liquide Hydrogen Energy World Business Line; Ken Ramirez, Executive Vice President, Hyundai Motor Group Energy & Hydrogen Business Division; Jaehoon Chang, Vice Chair, Hyundai Motor Group The partners announced the renewal of their Memorandum of Understanding (MoU) at the Hydrogen Council CEO Summit in Seoul. The partnership aims to lead to the expansion of a comprehensive hydrogen ecosystem, encompassing production, storage, transportation and utilization. The partnership will focus on scaling up hydrogen use across key regions, including Europe, Korea and the United States, with specific emphasis on heavy-duty transport, logistics and public transportation. By combining Air Liquide's technical expertise with the Group's leadership in mobility innovation, both companies will contribute to the development of a sustainable energy landscape and the achievement of carbon neutrality. "Hyundai Motor Group is proud to deepen its collaboration with Air Liquide to realize our shared vision of a hydrogen-powered future. Together, we are building a robust hydrogen value chain, from production to utilization, with the aim of making hydrogen a practical and sustainable solution for global energy challenges." – Ken Ramirez, Head of Energy & Hydrogen Business Division at Hyundai Motor Group "We are delighted to strengthen our partnership with Hyundai Motor Group. Collaborations like this between leaders across the value chain are essential to building the hydrogen economy. The progress we've made in Korea highlights what's possible when industry leaders work together for a sustainable future." – Armelle Levieux, Vice President of Innovation, Electronics and Hydrogen at Air Liquide Building a Global Hydrogen Ecosystem Infrastructure Expansion: Developing hydrogen refueling networks and storage capacity to meet growing demand. Reliable Supply Chain Development: Establishing a hydrogen ecosystem covering low carbon and renewable production, transportation, distribution, and utilization across mobility and other key sectors. A core element is also the acceleration of innovation in hydrogen technologies. Hydrogen Mobility Deployment: Commercializing fuel cell electric vehicles (FCEVs) for diverse applications, including logistics fleets, public buses and port operations. About Air Liquide More information about Air Liquide can be found at: https://www.airliquide.com/ or https://www.airliquide.com/group/press-releases-news About Hyundai Motor Group More information about Hyundai Motor Group can be found at: http://www.hyundaimotorgroup.com or Newsroom: Media Hub by Hyundai, Kia Global Media Center (kianewscenter.com), Genesis Newsroom
SYDNEY, Dec. 4, 2025 /PRNewswire/ -- Mobile communications leader Motorola has partnered with Swarovski® to launch its Motorola Collections series, The Brilliant Collection. The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose This thoughtfully curated set of select devices brings the new moto buds loop with Sound by Bose to Australia for the first time, accompanied by an elevated design of the renowned motorola razr 60 – both products encrusted with crystals by Swarovski®. The Brilliant Collection signifies how fashion and function can shine in perfect harmony, highlighting how fashion forward design and intelligent technology converge to not only meet the personal tech needs of Australians, but mirror their lives, styles, and values. On the partnership, Praveena Raman, Head of Motorola Australia and New Zealand says, "Motorola and Swarovski share a passion deeply rooted in innovation, craftsmanship and iconic heritage, making Swarovski a natural partner for the Motorola Collections series." "This collection brings lifestyle luxury to everyday technology. We have embodied Australians' desire for tech that elevates life, bridging beauty and functionality" Crystal clear sound meets crystal clear style: moto buds loop with Sound by Bose For the first time, the moto buds loop will be available in Australia - Motorola's first open-ear earbuds - available in an exquisite PANTONE™ Ice Melt colourway. Users can enjoy crystal-clear audio with Sound by Bose that sparkles as brilliantly as the Swarovski crystals, blending exceptional sound quality with distinctive personal style. The open-ear form allows users to stay connected to their environment while still experiencing great sound, perfect for commuting, running, or simply going about their day. Additionally, the sleek, lightweight frame and refined silhouette are crafted to sit securely and comfortably on the outer ear for a fit that feels as good as it looks, ideal for extended wear without fatigue. The meticulous attention invested in the stylish design has been matched by the innovative specs, with the earbuds delivering impressive audio thanks to the Sound by Bose technology, 12mm ironless drivers, and spatial sound technology, all delivering a rich, immersive listening experience. With a dual-microphone system and CrystalTalk AI, calls are clear with precise voice capture and minimized background noise. The moto buds loop are compatible with any Bluetooth device, and when paired with select Motorola devices, users can access helpful voice-activated actions thanks to moto ai1. Smart Connect also offers easy, uninterrupted switching between Motorola and Lenovo devices. Built for busy, on-the-go lifestyles, the moto buds loop feature durable materials, a water-repellent design2, and long-lasting battery life – up to eight hours on a single charge and 37 hours with the case3. The iconic flip phone now cuts a shine above the rest: motorola razr 60 The motorola razr 60, accented with dazzling Swarovski crystals, stands as the epitome of meticulous craftsmanship and timeless luxury. Featuring a shimmering leather-inspired finish in a 3D quilted pattern in mesmerising PANTONE Ice Melt, this device showcases 35 precisely hand-positioned Swarovski crystals, including one larger gem with 26 facets positioned on the hinge, delivering vibrant and sparkling brilliance. Even the volume keys feature a crystal-inspired design that adds an extra touch of elegance. Users can enjoy all the features that the motorola razr 60 has been praised for, from its 50MP camera system with moto ai integration delivering stunning photos in any light, to its 3.6" external display, offering access to favourite apps, without having to flip open the phone. The iconic razr design has always turned heads - now every crystal elevates its instantly recognisable silhouette, transforming it into a couture creation that radiates confidence and commands attention from every angle. The next chapter of lifestyle luxury and smart tech Motorola Collections are thoughtfully curated sets of select devices connected through inspired themes, cohesive design languages, or impactful brand collaborations. With every collection, Motorola will spotlight elite craftsmanship, purposeful innovation, and unexpected pairings that redefine how personal technology looks and feels. This dazzling collaboration is just the beginning for Motorola Collections, with limited quantities available and more curated device collections to follow. Availability The Brilliant Collection will be available in PANTONE Ice Melt, exclusively at Harvey Norman from 4 December 2025. The motorola razr 60 is available for RRP $1,499, and the moto buds loop with Sound by Bose is available for RRP $399. For a limited time, purchase the motorola razr 60 and moto buds loop in the same transaction and receive a $300 discount. Offer ends 24 December 2025. Terms and conditions apply. Follow Motorola Australia on Facebook, Instagram and TikTok. - ENDS – For full pricing information and specifications, visit motorola.com.au for further information or review devices, please contact the Motorola PR team at Zeno Group Legal disclaimers: MOTOROLA, the Stylised M Logo, MOTO and the MOTO family of marks are trademarks of Motorola Trademark Holdings, LLC. Bose and sound by Bose are trademarks of Bose Corporation. The Pantone colour reference and the PANTONE Chip Design are used with the permission of Pantone LLC. © Pantone LLC, 2025. All rights reserved. This is an authorized Pantone-licensed product manufactured by Motorola. Google and Android are trademarks of Google LLC. Swarovski® is a registered trademark of Swarovski AG. All other trademarks are the property of their respective owners. © 2025 Motorola Mobility LLC. moto ai features are only available on select Motorola devices. Water-repellent design creates a barrier to help protect against moderate exposure to fresh water such as accidental spills, splashes or light rain. Not designed to be submerged in water, or exposed to pressurized water, or other liquids; may diminish over time. Not waterproof. Battery must be substantially depleted; charging rate slows as charging progresses. All battery life claims are approximate and based on optimal conditions. Actual battery performance will vary and depends on many factors including device settings, temperature, battery condition, and usage patterns. The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose
Collaboration Previews the Upcoming Infinix NOTE 60 Ultra designed by Pininfarina HONG KONG, Dec. 3, 2025 /PRNewswire/ -- Today, during the Business of Design Week 2025, Infinix announced a landmark strategic partnership with Pininfarina, the iconic Italian design house with a 95-year legacy of shaping some of the world's most celebrated automobiles, as well as groundbreaking products across sectors such as luxury lifestyle, architecture and yachting. This collaboration marks the beginning of a new flagship design series, with the Infinix NOTE 60 Ultra set to become the first smartphone to emerge from this alliance. A photo captured at Business of Design Week 2025 shows a Pininfarina representative unveiling the new design partnership to the public. From the legendary curves of the Ferrari Testarossa to the iconic silhouette of the Alfa Romeo Spider, every creation bearing the Pininfarina badge has stood as a masterpiece of Italian design and innovation since 1930. Now Pininfarina brings its heritage and lifestyle - steeped in elegance and performance - to a smartphone. The upcoming "Infinix NOTE 60 Ultra design by Pininfarina", marks a milestone not only for the studio but for the industry. Infinix joins the collaboration at a moment of extraordinary global momentum, with shipments and market share soaring. According to IDC's Worldwide Quarterly Mobile Phone Tracker, Infinix achieved the largest quarter-on-quarter shipment increase in Southeast Asia in Q2 2025. By uniting Pininfarina's iconic design philosophy with Infinix's drive for technological innovation, the alliance aims to set a new benchmark for premium smartphone craftsmanship and introduce high-end, design-driven experiences to a global audience. "As we collaborate with leading partners across different fields, we are steadily advancing Infinix's journey toward premiumization," said Tony Zhao, CEO of Infinix. "Our work with Pininfarina is an important step in strengthening the design foundation of our future products, beginning with the NOTE 60 Series. This partnership reinforces our commitment to deepening investment in high-end design and establishing a new aesthetic benchmark for future flagship products." Fabio Calorio, Senior Vice President of Brand at Pininfarina, said: "Partnering with Infinix on this project has been a great opportunity both to express Pininfarina's legacy of Italian design excellence into the realm of technology and to apply our principles, based on the combination of beauty and performance, in order to make a lasting impact on the user experience. For nearly a century, our brand has shaped new ways of living, been synonymous with purity, timeless design, and emotion in form — values that perfectly align with Infinix's vision of innovation." A teaser poster featuring the Infinix × Pininfarina collaboration, hinting at the upcoming co-designed flagship device, the Infinix NOTE 60 Ultra. As Infinix and Pininfarina are gearing up to usher in a new era of premium mobile design, full details on the device's design philosophy, features, and availability will be announced in the coming days. About Infinix Established in 2013, Infinix is an innovation-driven brand dedicated to delivering cutting-edge technology, bold design, and outstanding performance. The brand provides smart, enjoyable mobile experiences that enhance everyday life. Beyond smartphones, Infinix has expanded its portfolio to include TWS earbuds, smartwatches, laptops, tablets, smart TVs, and more—building a comprehensive ecosystem of smart devices. Currently, Infinix products are available in over 70 countries and regions worldwide, including Africa, Latin America, the Middle East, South Asia, and Southeast Asia. For more information, please visit: http://www.infinixmobility.com/ About Pininfarina A global icon of Italian style, Pininfarina is recognised for its unparalleled ability to create timeless beauty through its values of elegance, purity, and innovation. Founded in 1930, Pininfarina has evolved from an artisan concern to an international service Group, supreme expression of automotive styling and an established reality in industrial and experience design, architecture, nautical and mobility beyond automotive. A group employing 500 people, offices in Italy, Germany, China, and the United States and listed on the Stock Exchange since 1986. Over the course of nine decades Pininfarina has designed more than 1450 automotive and mobility projects and more than 750 product and architecture projects, receiving more than 90 international design awards in past 10 years.
A12 藝術空間
PARTNERSHIP
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
